Carcinomatous or Polymorphous Skin LesionsSPECTROLIVENCT02956265
Optical Spectroscopy for Skin Carcinomas' Surgical Management
A study testing bimodal optical spectroscopy in people with Carcinomatous or Polymorphous Skin Lesions, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
Trial summary
Actinic keratosis are of utmost medical and economical interest because of their high prevalence (20 % of 60 year-old people and older in the Northern hemisphere) and their important cosmetic impact as such actinic keratosis mostly appear on photo-exposed skin sites. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Carcinomatous or Polymorphous Skin Lesions
- What is being tested?
- bimodal optical spectroscopy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 142 participants
- Where
- 1 siteFrance
- Study dates
- Oct 2016to 25 Mar 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults, and
- Autonomous: enjoying full citizenship rights and full mental abilities, and
- Affiliated to a social security system, and
- Suffering from carcinomatous or polymorphous skin lesions that can be fully managed in an outpatient (ambulatory) surgery procedure.
Who cannot join
- Carcinomatous or polymorphous skin lesions that require day admission, or
- Carcinomatous or polymorphous skin lesions for which resection margins are uncertain, or
- Naevomatous skin lesions and related skin pathologies.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment of Optical Spectroscopy's Diagnosis Accuracy When Non-invasively and Automatically Classifying Skin Lesions in One of the Following Histological Classes: Healthy, Actinic Keratosis, in Situ Carcinoma and Invasive Carcinoma.
Actinic keratosis are of utmost medical and economical interest because of their high prevalence (20 % of 60 year-old people and older in the Northern hemisphere) and their important cosmetic impact as such actinic keratosis mostly appear on photo-exposed skin sites. The surgeon in charge of such lesions' removal (i) some actinic keratosis adjoining carcinoma to be resected therefore causing the problem of functional areas damaging (eyelids, lips, etc.) or (ii) numerous actinic keratosis localized away from carcinoma (photo-carcinogenesis field) faces the issue of clinical evaluation of such lesions: which ones will spontaneously regress (it is supposed to be the case for 20 % of such lesions);which ones will remain and which ones will develop into invasive carcinomas ?
A non-invasive, non-traumatic, automated and real-time help for the clinical diagnosis orientation of such skin lesions could help improving diagnosis accuracy of the medical practitioner's visual inspection:
- In terms of sensitivity in order to potentially decrease the number of actinic keratosis evolving towards invasive carcinoma,
- In terms of specificity in order to potentially decrease useless resections and reduce resection margins and therefore reduce scars surface.
- Being tested
- bimodal optical spectroscopy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bimodal optical spectroscopyDevice
an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
| Study group | Role | What they receive |
|---|---|---|
| Patients - Suffering from carcinomatous or polymorphous skin | Experimental | Not described Receives: Device: bimodal optical spectroscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Optical spectroscopy's diagnostic validity for the 4 histological classes discrimination
Measured: day 1
Secondary outcomes (3)
Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between in situ carcinoma (ISC) and invasive carcinoma (InvC).
Measured: day 1
Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between 2 classes of actinic keratosis (AK) of clinical relevance: AK characterized by a "low" versus a "high" invasiveness risk
Measured: day 1
- Sensitivity and specificity of optical spectroscopy for discriminating the é molecular classes of actinic keratosis: AK characterized by a "low" versus a "high" invasiveness risk.
Measured: day 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Nov 2016 (estimated)
- Study startOct 2016
- Primary completion25 Mar 2021
- Study completion25 Mar 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Carcinomatous or Polymorphous Skin LesionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 142 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Régional Metz-Thionville
- Sponsor type
- University, hospital or other
- Collaborators
- University of Lorraine
- Responsible party
- Sponsor
- Investigators
- Grégoire Khairallah, Principal investigator, g.khairallah@chr-metz-thionville.fr
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02956265
- Sponsor's protocol ID
- 2016-05-CHRMT
- Acronym
- SPECTROLIVE
- Status last verified
- Apr 2026
- First submitted
- 3 Nov 2016
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Publications
Zghal A., Fauvel C., Kupriyanov V., Elsen T., Khairallah G., Blondel W., Amouroux M. Adv. Biomed. Clin. Diagn. Surg. Guid. Syst. XXI. SPIE; 2023. Human skin phototype and apparent age classification based on machine learning methods of autofluorescence and diffuse reflectance spectroscopic data acquired in vivo; pp. 60-64.
Blondel W., Delconte A., Khairallah G., Marchal F., Gavoille A., Amouroux M. Spatially-resolved multiply-excited autofluorescence and diffuse reflectance spectroscopy: spectrolive medical device for skin in vivo optical biopsy. Electronics. 2021;10:243. doi: 10.3390/electronics10030243.
Elsen T, Fauvel C, Khairallah G, Zghal A, Delconte A, Kupriyanov V, Blondel W, Amouroux M. A dataset of optical spectra and clinical features acquired on human healthy skin and on skin carcinomas. Data Brief. 2024 Feb 6;53:110163. doi: 10.1016/j.dib.2024.110163. eCollection 2024 Apr.
PubMed 38375145
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of Optical Spectroscopy's Diagnosis Accuracy When Non-invasively and Automatically Classifying Skin Lesions in One of the Following Histological Classes: Healthy, Actinic Keratosis, in Situ Carcinoma and Invasive Carcinoma.
- ClinicalTrials.gov ID
- NCT02956265
- Acronym / sponsor ID
- SPECTROLIVE / 2016-05-CHRMT
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 142 participants (actual)
- Lead sponsor
- Centre Hospitalier Régional Metz-ThionvilleUniversity, hospital or other
- Collaborators
- University of Lorraine
- Study start
- Oct 2016
- Primary completion
- 25 Mar 2021 (actual)
- Study completion
- 25 Mar 2021 (actual)
- First posted
- 7 Nov 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Actinic keratosis are of utmost medical and economical interest because of their high prevalence (20 % of 60 year-old people and older in the Northern hemisphere) and their important cosmetic impact as such actinic keratosis mostly appear on photo-exposed skin sites. The surgeon in charge of such lesions' removal (i) some actinic keratosis adjoining carcinoma to be resected therefore causing the problem of functional areas damaging (eyelids, lips, etc.) or (ii) numerous actinic keratosis localized away from carcinoma (photo-carcinogenesis field) faces the issue of clinical evaluation of such lesions: which ones will spontaneously regress (it is supposed to be the case for 20 % of such lesions);which ones will remain and which ones will develop into invasive carcinomas ?
A non-invasive, non-traumatic, automated and real-time help for the clinical diagnosis orientation of such skin lesions could help improving diagnosis accuracy of the medical practitioner's visual inspection:
- In terms of sensitivity in order to potentially decrease the number of actinic keratosis evolving towards invasive carcinoma,
- In terms of specificity in order to potentially decrease useless resections and reduce resection margins and therefore reduce scars surface.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients - Suffering from carcinomatous or polymorphous skin | Experimental | Device: bimodal optical spectroscopy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Adults, and
- Autonomous: enjoying full citizenship rights and full mental abilities, and
- Affiliated to a social security system, and
- Suffering from carcinomatous or polymorphous skin lesions that can be fully managed in an outpatient (ambulatory) surgery procedure.
Key exclusion criteria (3 listed)
- Carcinomatous or polymorphous skin lesions that require day admission, or
- Carcinomatous or polymorphous skin lesions for which resection margins are uncertain, or
- Naevomatous skin lesions and related skin pathologies.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bimodal optical spectroscopyan optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra | Device | Patients - Suffering from carcinomatous or polymorphous skin |
Primary outcome
Optical spectroscopy's diagnostic validity for the 4 histological classes discrimination
Time frame: day 1
3 secondary outcomes
Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between in situ carcinoma (ISC) and invasive carcinoma (InvC).
Time frame: day 1
Statistical significance degree of the discrimination by molecular profiling (transcriptomic characterization) between 2 classes of actinic keratosis (AK) of clinical relevance: AK characterized by a "low" versus a "high" invasiveness risk
Time frame: day 1
- Sensitivity and specificity of optical spectroscopy for discriminating the é molecular classes of actinic keratosis: AK characterized by a "low" versus a "high" invasiveness risk.
Time frame: day 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Results publicationZghal A., Fauvel C., Kupriyanov V., Elsen T., Khairallah G., Blondel W., Amouroux M. Adv. Biomed. Clin. Diagn. Surg. Guid. Syst. XXI. SPIE; 2023. Human skin phototype and apparent age classification based on machine learning methods of autofluorescence and diffuse reflectance spectroscopic data acquired in vivo; pp. 60-64.
- Results publicationBlondel W., Delconte A., Khairallah G., Marchal F., Gavoille A., Amouroux M. Spatially-resolved multiply-excited autofluorescence and diffuse reflectance spectroscopy: spectrolive medical device for skin in vivo optical biopsy. Electronics. 2021;10:243. doi: 10.3390/electronics10030243.
- Results publication: PubMed 38375145Elsen T, Fauvel C, Khairallah G, Zghal A, Delconte A, Kupriyanov V, Blondel W, Amouroux M. A dataset of optical spectra and clinical features acquired on human healthy skin and on skin carcinomas. Data Brief. 2024 Feb 6;53:110163. doi: 10.1016/j.dib.2024.110163. eCollection 2024 Apr.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Grégoire Khairallah principal investigator
g.khairallah@chr-metz-thionville.fr
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bimodal optical spectroscopy in people with Carcinomatous or Polymorphous Skin Lesions, run by Centre Hospitalier Régional Metz-Thionville at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Optical spectroscopy's diagnostic validity for the 4 histological classes discrimination (time frame: day 1). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02956265, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.